Video Experimental Relacionado
Updated: Sep 10, 2025
06:15
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
50.4K
Displasia broncopulmonar en el primer año: información sobre la gravedad, el uso de medicamentos y la utilización de
Eliaz Brumer1,2, Veronika Shabanova2,3, Haley Urbach2
1Department of Pediatrics, Section of Pulmonary, Allergy-Immunology, and Sleep Medicine, Yale University, New Haven, Connecticut, USA.
Pediatric pulmonology
|August 26, 2025
Resumen
Los bebés con displasia broncopulmonar (BP) enfrentan problemas respiratorios significativos y necesidades de atención médica después del alta, que aumentan con la gravedad de la enfermedad. El seguimiento estructurado es crucial para todos los pacientes con TLP, independientemente de la gravedad, para controlar la morbilidad respiratoria.
Área de la Ciencia:
- Medicina neonatal
- Pulmonología pediátrica
- Medicina de las vías respiratorias
Sus antecedentes:
- La displasia broncopulmonar (BP) es una enfermedad pulmonar crónica prevalente en los bebés prematuros.
- Comprender el impacto de la gravedad del TLP en los resultados respiratorios y el uso de la atención médica es fundamental para optimizar la atención.
- El papel de las intervenciones de la UCIN como la dexametasona y el seguimiento posterior a la UCIN requiere una caracterización adicional.
Objetivo del estudio:
- Examinar la asociación entre la gravedad del TLP y los resultados respiratorios posteriores a la UCI y la utilización de la atención médica.
- Evaluar el impacto del seguimiento pulmonológico pediátrico en la morbilidad respiratoria.
- Evaluar la influencia de la administración de dexametasona durante la estancia en la UCIN en la salud respiratoria después del alta.
Principales métodos:
- Estudio de cohorte retrospectivo de 161 niños diagnosticados con TLP (2021-2023) utilizando la clasificación de gravedad de 2019.
- Resultados clave evaluados: recetas de medicamentos (albuterol, esteroides inhalados / sistémicos), visitas a urgencias y hospitalizaciones dentro de un año después del alta de la UCIN.
- Análisis del uso de dexametasona, seguimiento pulmonológico y asociaciones de morbilidad respiratoria.
Principales resultados:
- Distribución de la gravedad del TLP: 32,9% de grado 1, 59,0% de grado 2, 8,1% de grado 3.
- El uso de dexametasona y las tasas de seguimiento pulmonológico aumentaron con la gravedad de la DBP (p< 0,001).
- Casi la mitad (47,2%) experimentó visitas al hospital respiratorio después del alta; el 22,3% fue hospitalizado.
Conclusiones:
- La morbilidad respiratoria y la utilización de la atención médica en niños con TLP aumentan con la gravedad de la enfermedad.
- Existe una carga significativa de visitas hospitalarias respiratorias en todos los niveles de gravedad del TLP, incluidos los casos más leves.
- El seguimiento longitudinal estructurado es esencial para todos los niños con TLP para mitigar la morbilidad respiratoria.
Videos de Conceptos Relacionados
01:23Inhaled Medications
388
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
388
01:17Pulmonary Cycle: Exhalation
1.8K
In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
1.8K
01:26COPD: Management Using Bronchodilators and Corticosteroids
307
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
307
01:17Drugs Used in Lower Respiratory Disorders: Overview
578
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
578
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.9K